Correlation Between MG Symptoms PRO and Existing MG-Specific Outcome Scores in the Phase 3 MycarinG Study: Post Hoc Analysis (P1-11.026)
To evaluate the correlation between Myasthenia Gravis (MG) Symptoms Patient-Reported Outcome (MG Symptoms PRO) scale scores and MG Activities of Daily Living (MG-ADL) and Quantitative MG (QMG) subdomain scores using data from the Phase 3 MycarinG study (NCT03971422) of rozanolixizumab in patients with generalized MG.
Authors
- Jos Bloemers (ORCID: https://orcid.org/0000-0001-5637-7606)
- Kimiaki Utsugisawa (ORCID: https://orcid.org/0000-0001-9373-8167)
- Carlo Antozzi (ORCID: https://orcid.org/0000-0001-9270-5224)
- Antoine Regnault (ORCID: https://orcid.org/0000-0001-8234-2896)
- Henry J. Kaminski (ORCID: https://orcid.org/0000-0002-8195-0141)
- Sabrina Sacconi (ORCID: https://orcid.org/0000-0002-0246-1455)
- Fiona Grimson
- Robert M. Pascuzzi (ORCID: https://orcid.org/0000-0003-0616-3073)
- Vera Bril (ORCID: https://orcid.org/0000-0002-5805-4883)
- Thaïs Tarancón
- Ali A. Habib (ORCID: https://orcid.org/0000-0003-3432-9747)
- John Vissing
Institutions
- University of Copenhagen (DK)
- Indiana University Health (US)
- University Health Network (CA)
- George Washington University (US)
- Université Côte d'Azur (FR)
- University of California, Irvine (US)
- Rigshospitalet (DK)
- Centre Hospitalier Universitaire de Nice (FR)
- National Hospital Organization Hanamaki Hospital (JP)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- Indiana University – Purdue University Indianapolis (US)
- UCB Pharma (Belgium) (BE)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208794
- Primary Topic
- Voice and Speech Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00